{"filings":[{"id":116073,"accession_number":"0001477932-26-001252","cik":924515,"company_name":"GUIDED THERAPEUTICS INC","ticker":"GTHP","form_type":"8-K","filed_at":"2026-03-10T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Guided Therapeutics completes warrant exchange; issues 4.825M shares for $980K cash","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Holders of 4.825M eligible warrants (22.7% of total) tendered; exchanged for restricted common stock at reduced exercise prices.","Exercise price for $0.65 warrants reduced to $0.25; for $0.50 warrants reduced to $0.20, generating $980K total cash proceeds.","After exchange, company has 91.5M shares outstanding; 16.4M eligible warrants remain, most expiring Sep–Oct 2026.","Remaining unexercised warrants held by participating holders have expiration extended by one year.","Shares issued under Section 3(a)(9) exemption; no commissions paid for solicitation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":22107053.75263158,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":201828,"accession_number":"0001477932-24-008254","cik":924515,"company_name":"GUIDED THERAPEUTICS INC","ticker":"GTHP","form_type":"8-K","filed_at":"2024-12-23T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Guided Therapeutics raises $535K in private placement; issues shares and warrants at $0.13/unit","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of $535,000 from sale of 4,115,386 shares and warrants to purchase same number.","Combined purchase price $0.13 per share and warrant; exercise price $0.18, expiration 4 years.","Investor includes board member John Imhoff.","Net proceeds for working capital and manufacturing expenses to fill recent international distribution orders."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":22107053.75263158,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":217837,"accession_number":"0001477932-24-005960","cik":924515,"company_name":"GUIDED THERAPEUTICS INC","ticker":"GTHP","form_type":"8-K","filed_at":"2024-09-27T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Guided Therapeutics raises $300,000 in private placement of common stock and warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of $300,000 from sale of 3,333,335 shares and warrants to purchase 3,333,335 shares.","Combined purchase price per share and warrant is $0.09; warrants exercisable at $0.12 for 4 years.","Board member John Imhoff is among the institutional investors participating in the offering.","Net proceeds to be used for general corporate purposes and working capital.","Closing occurred on September 23, 2024 with immediate exercisability of warrants."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":22107053.75263158,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":329084,"accession_number":"0001477932-23-001383","cik":924515,"company_name":"GUIDED THERAPEUTICS INC","ticker":"GTHP","form_type":"8-K","filed_at":"2023-03-09T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Guided Therapeutics CEO Gene Cartwright retires; Mark Faupel appointed as successor","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Gene Cartwright retired as President, CEO, and Board member effective March 3, 2023; no disagreement cited.","Board appointed COO Dr. Mark Faupel (Ph.D., 67) as President and CEO effective March 6, 2023; he was CEO from 2007-2013.","Alan Grujic appointed to Board effective March 8, 2023; brings finance and hedge fund experience.","Faupel's compensation as CEO to be determined later by compensation committee.","Grujic is not appointed to any Board committees; no related-party transactions disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":22107053.75263158,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":363099,"accession_number":"0001477932-22-006945","cik":924515,"company_name":"GUIDED THERAPEUTICS INC","ticker":"GTHP","form_type":"8-K","filed_at":"2022-09-15T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Guided Therapeutics closes $3.3M bridge financing, exchanges Auctus debt, targets FDA study completion","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Raised ~$3.3M via 6.6M shares at $0.50 each, plus four-year warrants for 6.6M shares at $0.50 and 6.6M at $0.65.","Auctus exchanged $1.06M debt and 8.78M warrants for $1.95M in units (3.9M shares, 3.9M warrants at $0.50 and $0.65); residual $490K debt over 18 months.","Net proceeds ~$3.2M; primary use to fund clinical study data for FDA approval of LuViva Advanced Cervical Scan, also support international sales and reduce debt.","Stockholders' equity nearly break-even; Company to withdraw S-1/A for Nasdaq uplist and reapply when market conditions improve.","Investors include board members Richard Blumberg, Michael James, John Imhoff."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":22107053.75263158,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":363098,"accession_number":"0001477932-22-005479","cik":924515,"company_name":"GUIDED THERAPEUTICS INC","ticker":"GTHP","form_type":"8-K","filed_at":"2022-07-29T23:59:59+00:00","items":["3.03","5.03","9.01"],"status":"ready","headline":"Guided Therapeutics cancels previously approved 1-for-20 reverse stock split, renders amendment void","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Certificate of Correction filed July 25, 2022, nullifies December 30, 2021 reverse split amendment ab initio.","FINRA never declared the reverse split effective, so it was never implemented on the OTC Market.","Reverse stock split ratio of up to 1-for-20 was approved by stockholders in July 2021 and board in December 2021."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":22107053.75263158,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":400656,"accession_number":"0001654954-22-000294","cik":924515,"company_name":"GUIDED THERAPEUTICS INC","ticker":"GTHP","form_type":"8-K","filed_at":"2022-01-07T23:59:59+00:00","items":["3.03","5.03","9.01"],"status":"ready","headline":"Guided Therapeutics approves 1-for-20 reverse stock split; FINRA effective date pending","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board approved 1-for-20 reverse split on Dec 30, 2021; Certificate of Amendment filed with Delaware.","Each 20 shares reclassified into 1 share; no fractional shares issued, whole share granted instead.","Options, warrants, and convertible securities adjusted proportionally to reflect the split.","Stockholder approval obtained in July 2021; FINRA has not yet declared effective date."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":22107053.75263158,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":437188,"accession_number":"0001654954-21-009799","cik":924515,"company_name":"GUIDED THERAPEUTICS INC","ticker":"GTHP","form_type":"8-K","filed_at":"2021-09-07T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Guided Therapeutics passes regulatory review in China; receives $133K payment from SMI","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Clinical trial at Fudan University approved; trials at 4 centers start Q3 2021.","SMI paid $133,000 first installment; total $510,635 due during study.","Expected payments up to $3M by end 2022 if NMPA approval granted.","Minimum orders of $72M over 4 years post Chinese FDA approval.","LuViva disposable royalty set at $1.90 per unit, adjusted for inflation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":22107053.75263158,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":437187,"accession_number":"0001121781-21-000023","cik":924515,"company_name":"GUIDED THERAPEUTICS INC","ticker":"GTHP","form_type":"8-K","filed_at":"2021-07-27T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Guided Therapeutics shareholders approve reverse split and charter changes at annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All seven proposals approved at July 22, 2021 annual meeting.","Reverse split up to 1-for-20 authorized; board may decide by Dec 31, 2021; 15.58M for.","Authorized common reduced from 3B to 500M shares; 15.69M for.","Series F preferred authorized increased to 4,000 from 1,500; 15.51M for.","Advisory compensation vote and one-year frequency approved."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":22107053.75263158,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":437186,"accession_number":"0001121781-21-000019","cik":924515,"company_name":"GUIDED THERAPEUTICS INC","ticker":"GTHP","form_type":"8-K","filed_at":"2021-07-07T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Guided Therapeutics schedules 2021 Annual Meeting for July 22; proposal deadline July 16","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Annual Meeting will be held July 22, 2021 at 10:00 a.m. local time.","Stockholder proposals and director nominations must be received by July 16, 2021.","Board made the determination on June 6, 2021."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.05,"calibrated_materiality_score":0.05,"market_cap_usd":22107053.75263158,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}